Ascendis Pharma A/S (NASDAQ:ASND) Now Covered by Raymond James Financial

Raymond James Financial started coverage on shares of Ascendis Pharma A/S (NASDAQ:ASND) in a research report released on Friday morning, MarketBeat Ratings reports. The brokerage issued a strong-buy rating and a $271.00 price objective on the biotechnology company’s stock.

Other research analysts also recently issued reports about the stock. Citigroup restated a “buy” rating and issued a $290.00 target price (up from $243.00) on shares of Ascendis Pharma A/S in a research note on Friday, August 8th. Cantor Fitzgerald upped their target price on shares of Ascendis Pharma A/S from $203.00 to $254.00 and gave the company an “overweight” rating in a research note on Monday. Morgan Stanley began coverage on shares of Ascendis Pharma A/S in a research note on Thursday, July 3rd. They issued an “overweight” rating and a $250.00 target price for the company. Stifel Nicolaus upped their target price on shares of Ascendis Pharma A/S from $212.00 to $254.00 and gave the company a “buy” rating in a research note on Friday, August 8th. Finally, Bank of America upped their target price on shares of Ascendis Pharma A/S from $227.00 to $230.00 and gave the company a “buy” rating in a research note on Tuesday, September 2nd. One investment analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, Ascendis Pharma A/S presently has a consensus rating of “Moderate Buy” and a consensus target price of $249.80.

Ascendis Pharma A/S Stock Performance

Shares of ASND opened at $210.50 on Friday. The company has a market capitalization of $12.99 billion, a price-to-earnings ratio of -40.79 and a beta of 0.41. The company’s 50 day simple moving average is $199.16 and its 200 day simple moving average is $177.47. Ascendis Pharma A/S has a 1 year low of $118.03 and a 1 year high of $216.45.

Ascendis Pharma A/S (NASDAQ:ASND) last posted its quarterly earnings results on Thursday, August 7th. The biotechnology company reported ($0.93) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.42) by $0.49. The company had revenue of $216.28 million for the quarter, compared to analysts’ expectations of $163.17 million. Equities analysts expect that Ascendis Pharma A/S will post -4.34 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the stock. Burns Matteson Capital Management LLC bought a new position in shares of Ascendis Pharma A/S in the 3rd quarter worth about $257,000. Farther Finance Advisors LLC lifted its position in shares of Ascendis Pharma A/S by 115.3% in the 3rd quarter. Farther Finance Advisors LLC now owns 478 shares of the biotechnology company’s stock worth $95,000 after buying an additional 256 shares during the last quarter. Toth Financial Advisory Corp lifted its position in shares of Ascendis Pharma A/S by 33.7% in the 3rd quarter. Toth Financial Advisory Corp now owns 595 shares of the biotechnology company’s stock worth $118,000 after buying an additional 150 shares during the last quarter. Whalen Wealth Management Inc. bought a new position in shares of Ascendis Pharma A/S in the 3rd quarter worth about $919,000. Finally, GAMMA Investing LLC lifted its position in shares of Ascendis Pharma A/S by 15.2% in the 3rd quarter. GAMMA Investing LLC now owns 735 shares of the biotechnology company’s stock worth $146,000 after buying an additional 97 shares during the last quarter.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.